Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Shahzad M, et al. Front Immunol. 2023 Apr 24;14:1152457. doi: 10.3389/fimmu.2023.1152457. eCollection 2023. Front Immunol. 2023. PMID: 37168849 Free PMC article. Review.
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU, Shahzad M, Chaudhary SG, Luder M, Ahmed N, Abdelhakim H, Bansal R, Balusu R, DeJarnette S, Divine C, Kribs R, Shune L, Singh AK, Ganguly S, Abhyankar SH, McGuirk JP. Mushtaq MU, et al. Among authors: shahzad m. Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10. Transplant Cell Ther. 2021. PMID: 34256172 Free PMC article.
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, Ahmed TF, Ahmed Z, Khurana S, Ahmed N, Balusu R, Singh AK, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Transplant Cell Ther. 2021 Oct;27(10):877.e1-877.e8. doi: 10.1016/j.jtct.2021.07.012. Epub 2021 Jul 18. Transplant Cell Ther. 2021. PMID: 34284148 Free article.
Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A, Hashim L, Faisal MS, Haider MZ, Ahmed Z, Ahmed TF, Shahzad M, Ansar I, Ali S, Aslam MM, Anwer F. Sarwar A, et al. Among authors: shahzad m. Expert Rev Hematol. 2021 Dec;14(12):1071-1083. doi: 10.1080/17474086.2021.1972802. Epub 2021 Sep 15. Expert Rev Hematol. 2021. PMID: 34428997 Review.
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L. Ahmed N, et al. Among authors: shahzad m. Transplant Cell Ther. 2022 Jul;28(7):358-364. doi: 10.1016/j.jtct.2022.04.008. Epub 2022 Apr 13. Transplant Cell Ther. 2022. PMID: 35429662 Free article. Clinical Trial.
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
Khanam R, Shahzad M, Chaudhary SG, Ali F, Shah Z, Pachika PS, Ahmed Z, Chattaraj A, Masood A, Ahmed N, Bansal R, Balusu R, Shune L, Anwar F, Hematti P, McGuirk JP, Yacoub A, Mushtaq MU. Khanam R, et al. Among authors: shahzad m. Leuk Lymphoma. 2022 Nov;63(11):2671-2678. doi: 10.1080/10428194.2022.2084730. Epub 2022 Jun 10. Leuk Lymphoma. 2022. PMID: 35687838
703 results